Today, Chairman McCaskill requested that the Department of Homeland Security’s Office of Inspector General and Department of Defense’s Office of Inspector General review the decision to buy $334 million worth of an anthrax antitoxin known as raxibacumab (raxi) from Human Genome Services, Inc. Chairman McCaskill raised serious concerns about the decision to buy the antitoxin when its efficacy against anthrax is unproven.